Plasmid vs Chromosomal Integration Strategy & Stability Testing

Late-stage development and clinical translation of engineered strains generally seek to avoid the use of antibiotic resistance markers due to the risk of horizontal gene transfer (HGT) to the host microbiome. Without these markers, plasmids can be lost during cell division (segregational instability), causing a drop in therapeutic efficacy. Chromosomal integration anchors the payload into the genome, providing evidence for inheritance across generations without selective pressure, while often presenting a more manageable metabolic burden on the cell.

We utilize advanced bioinformatics to map the host genome and identify "safe harbor" sites—intergenic regions or non-essential loci where gene insertion is less likely to disrupt crucial metabolic pathways or native gene regulation. Post-integration, we conduct phenotypic validations and whole genome sequencing (WGS) to document that host fitness parameters (e.g., growth rate, viability) align with expectations.

While traditional single-copy integration might yield lower expression than high-copy plasmids, we can evaluate advanced strategies to address this. This includes assessing ultra-strong synthetic promoters, integrating constructs into highly transcribed regions (like rRNA operons), or evaluating multi-copy chromosomal integration pathways to provide improved expression profiles while seeking to maintain markerless stability.

Our standard in vitro selection-free passaging assays typically run for 50 to 100+ generations, evaluating parameters against project-specific acceptance criteria. We analyze percentage retention, copy number drift, relative expression variation, and phenotypic consistency to provide datasets that support stability evaluations for scale-up fermentation and downstream analytics.